Arginine Vasopressin Receptor Antagonists for Heart Failure

eart failure (HF) is among the most common causes of ospitalization, and its incidence will likely increase in an ging population of “survivors” (1). Pharmacological treatent targeted at neurohormonal activation has improved urvival, but mortality remains substantial in patients with F, thus warranting the search for novel therapeutic aproaches. Novel agents under investigation for the treatent of HF include arginine vasopressin (AVP) receptor ntagonists (RA). Udelson et al. (2), in this issue of the ournal, report the effects of an AVPRA, tolvaptan, on left entricular (LV) remodeling in patients with systolic HF.